Tests atezolizumab, bevacizumab and radiotherapy in liver cancer that cannot be removed by surgery

Trial details

Who runs it

Chang Gung Memorial Hospital

Trial code

NCT06339424

Record updated

1 October 2026

Original description

Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the established standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Despite an improved objective response rate (ORR) of 27%, the majority of patients face HCC progression and liver failure [Finn et al., N Engl J Med 2020]. Developing a new combined treatment strategy to overcome resistance to anti-PD-L1 and anti-VEGF is essential to improve patient outcomes.Read full original descriptionShow less

Investigation of Antitumor Immune Response in Patients With Unresectable Hepatocellular Carcinoma Undergoing Photon Radiotherapy Combined With Atezolizumab and Bevacizumab

Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the established standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC). Despite an improved objective response rate (ORR) of 27%, the majority of patients face HCC progression and liver failure [Finn et al., N Engl J Med 2020]. Developing a new combined treatment strategy to overcome resistance to anti-PD-L1 and anti-VEGF is essential to improve patient outcomes.

Radiation treatment (RT) is highly efficacious in controlling localized solid tumors and has become an integral component of the treatment algorithm for unresectable HCC. Importantly, a recent retrospective cohort described that RT combined with atezolizumab plus bevacizumab was associated with favorable median overall survival of 16.1 months (Manzar et al, Cancers 2022). Our preclinical study (Hsieh et al., Science Immunology 2022) revealed that RT combined with PD-L1/PD-1 blockade induces immunogenic cell death and tumor antigen cross-presentation in antigen-presenting cells, thereby potentiating the systemic antitumor T cell responses in murine tumor models. However, whether the combinatorial therapy with RT, atezolizumab, and bevacizumab can trigger synergistic antitumor effects and systemic immune mobilization has not yet been validated in clinical trials for unresectable HCC.

Both atezolizumab/bevacizumab and X-ray RT are approved treatment methods for unresectable HCC by the U.S. and Taiwan Food and Drug Administration (FDA). The present phase II non-randomized trial aims to prospectively document the therapeutic efficacy, safety, and immunological responses in patients with unresectable HCC treated with atezolizumab/bevacizumab combined with conventional photon radiotherapy.

Inclusion: Participants must have a diagnosis of HCC that is deemed unsuitable for surgical resection or transplant. Participants may have multiple lesions with a total maximal tumor dimension of < 20 cm, and no one lesion > 15 cm. Diagnosis should be confirmed by at least 1 criterion listed below:; Histologically or cytologically proven diagnosis of HCC; Typical arterial enhancement and delayed washout on multiphasic CT or MRI; Age ≥18 years at the time of signing the informed consent document; ECOG performance status 0-1; Barcelona Clinic Liver Cancer (BCLC) stages Intermediate (B) or Advanced (C); Child-Pugh score 5-6 liver function within 28 days of study registration; Documented virology status of hepatitis B virus (HBV), as confirmed by screening HBV serology test; Documented virology status of hepatitis C virus (HCV), as confirmed by screening HCV serology test; Ability to understand and the willingness to sign a written informed consent document; Adequate bone marrow, liver, and renal function within 4 weeks before study registration; Hemoglobin ≥ 9.0 g/dL; Absolute neutrophil count (ANC) ≥ 1,000/mm3; Platelet count ≥ 50,000/μL; Total bilirubin < 2.5 mg/dL; Serum albumin >2.8 g/dL; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper limit of normal (ULN); Prothrombin time ≤ 6 seconds prolonged; Serum creatinine ≤ 1.5 mg/dL.

Exclusion: Prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields; Prior selective internal radiotherapy/hepatic arterial yttrium therapy, at any time; Presence of distant metastases that cannot be encompassed by photon radiotherapy; Severe, active co-morbidity, defined as follows:; Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration; Myocardial infarction within the last 6 months prior to study entry; Acute bacterial or fungal infection requiring intravenous antibiotics within 28 days prior to study entry; A bleeding episode within 6 months prior to study entry due to any cause; Thrombolytic therapy within 28 days prior to study entry; Known bleeding or clotting disorder; Uncontrolled psychotic disorder; Prior solid organ transplantation; Prior or active autoimmune disease (AID) including autoimmune hepatitis, inflammatory bowel disease, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, and multiple sclerosis; Prior or active thrombotic or bleeding disorders, hemoptysis, cerebral vascular accident, significant cardiac disease (ischemic or congestive heart failure), or gastrointestinal perforation; Prior invasive malignancy unless disease-free for a minimum of 2 years; Untreated active hepatitis B or hepatitis C; Inability to treat all sites of disease by photon radiotherapy (such as extrahepatic metastases or massive liver tumors whereby the liver constraints cannot be met for covering all sites of liver tumors.); Known HIV infection; Moderate to severe or intractable ascites; Untreated or incompletely treated esophageal or gastric varices; Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception.

ClinicalTrials.gov NCT06339424